Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Strategic combination will accelerate development of extended phage therapies for antimicrobial resistance including Anti-Staphylococcus aureus Bacteriophages, in particular via the phase II PhagoDAIR study conducted by PHERECYDES.
Lead Product(s): Anti-Staphylococcus Aureus Bacteriophage
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Erytech Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger February 15, 2023